Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This pilot clinical trial studies magnetic resonance imaging (MRI)-guided stereotactic body radiation therapy (SBRT) in treating patients with liver metastases or liver cancer. SBRT is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue. Combining MRI with SBRT may help doctors to highlight the tissues surrounding the tumor better.
Full description
PRIMARY OBJECTIVES:
I. To assess the feasibility of utilizing an MRI-guided tri-60Co teletherapy system for liver SBRT, as determined the treating radiation oncologist's ability to accurately visualize and align to the target lesion(s).
II. To assess the feasibility of using a three versus five fraction scheme, for one versus multiple (i.e., =< 5) target lesions.
SECONDARY OBJECTIVES:
I. To determine the tumor local control (LC), disease specific survival (DSS), and overall survival (OS).
II. To gather biomarkers that may elucidate differential immunogenic responses from the three versus the five fraction SBRT regimens.
OUTLINE:
Patients undergo MRI-guided Tri-60Co teletherapy SBRT 3-5 fractions over 1-2 weeks.
After completion of study treatment, patients are followed up at approximately 4-6 weeks, and then every 3 months for 2 years.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
21 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal